Merck & Co., Inc. (MRK)
Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster
Shares of Summit Therapeutics Inc. SMMT, +272.06% jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.'s blockbuster Keytruda in a late-stage clinical trial.
Merck (MRK) to Buy Private Ophthalmology Company EyeBio
Merck's (MRK) acquisition of EyeBio is set to add the latter's lead pipeline candidate, Restoret, a novel Wnt agonist antibody being developed for treating retinal diseases.
Merck acquires EyeBio in up to $3B deal
Merck & Co Inc (NYSE:MRK, ETR:6MK) announced it is acquiring Eyebio, a privately held ophthalmology-focused biotech firm, in a deal valued up to $3 billion. Through a subsidiary, Merck will acquire Eyebio for an upfront payment of $1.3 billion in cash with a further potential $1.7 billion in development, regulatory and commercial milestone payments.
Merck Stock: Still Discounted To Graham P/E
Merck stock is still a buy despite near-record stock prices. Thanks to its growth outlook, its current valuation is still far below the Graham P/E, leaving a wide margin of safety. Its well-balanced business model, top-grossing Keytruda franchise, and superb financial strength further skew the return/risk profile.
Merck to Buy Eye Drug Startup For Up to $3 Billion. It's Doubling Down on Deals.
The pharmaceutical company agreed to buy eye drug company Eyebiotech for up to $3 billion as it moves to diversify its pipeline and intensifies its acquisition efforts.
Merck to acquire eye drug company EyeBio for up to $3 bln
Merck said on Wednesday it would acquire eye disease drug developer EyeBio for up to $3 billion, in the latest acquisition by the U.S. drugmaker as it looks to boost growth.
Merck to buy EyeBio in a deal that could valued at up to $3 billion
Merck & Co. Inc. MRK, -2.63% announced Wednesday an agreement to buy privately held Eyebiotech Ltd., an ophthalmology-focused biotechnology company, in a deal that could be valued at up to $3 billion.
Merck nears $1.3 bln cash deal for eye-drug company EyeBio, WSJ reports
Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, the Wall Street Journal reported on Tuesday.
Sell Alert: 2 Dividend Stocks To Sell In May And Go Away
The "Sell in May and go away" adage suggests selling stocks in May and returning in November, but historical data shows that June and July have been strong months. September is consistently the worst month for the stock market, with unpredictable returns, while November has historically been the best month. Selling stocks should be based on valuation rather than following a seasonal strategy, focusing on rotating out of overvalued stocks and into undervalued ones.
HPV vaccine provides real benefits for men, analysis shows
Vaccination of boys and men against the human papillomavirus (HPV) reduces their risk of head and neck cancers and other malignancies, a new analysis shows, adding to the vaccine's proven benefit in protecting women from cervical cancer.
HPV vaccine can have big benefits for men, research shows
A vaccine that's widely known to help protect women from cervical cancer can also offer big health benefits for men, new research shows.
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
